Biomarin
BioMarin develops and commercialises innovative biopharmaceuticals for rare diseases driven by genetic causes.
Financial Data
-
31st Dec 18 Source: CRO
- €1.1 billion turnover
-
€43 million
profit - 385 employees
-
31st Dec 17 Source: CRO
- €491.6 million turnover
-
€1 million
profit - 300 employees
- 3 more years available »
Ranking
By Turnover
(€1.1 billion)- 84th in Top Companies
- 13th in Health
By Employees
(385)- 430th in Top Companies
- 64th in Health
- 385
- €1.1 billion
Employees
- Michael O’Donnell CEO/Managing Director
Latest News
- 5:16am CRH chief’s €9.3m pay package under scrutiny as Covid-19 impacts earnings
- 4:00am Debt market freeze hits sour note for Bank of Ireland
- Apr 03 Primark sets up fund for factory workers hit by Covid-19 order cancellations
- Apr 03 European shares decline over fears of deep recession
- Apr 03 Court rules Cox cannot access O’Flynn papers in legal dispute